Top

The European Journal of Health Economics

Published in:

01-01-2018 | Editorial

Competition in pharmaceuticals: more product- than price-oriented?

Authors: Livio Garattini, Anna Padula

Published in: The European Journal of Health Economics | Issue 1/2018

Excerpt

Competition is a subject always open to debate in health care, and pharmaceuticals are no exception, with the only clear difference from other ‘markets’ (e.g. hospital services) being that the supply side is private industry, worldwide. …

Garattini, L., Cornago, D., De Compadri, P.: Pricing and reimbursement of in-patent drugs in seven European countries: a comparative analysis. Health Policy 82(3), 330–339 (2007)CrossRef

Bennett, S., Quick, J.D., Velásquez, G.: Public-private roles in the pharmaceutical sector: implications for equitable access and rational drug use. WHO/DAP/97.12. World Health Organization, Geneva (1997)

Machovec, F.M.: Perfect competition and the transformation of economics. Routledge, London (1995)CrossRef

Cheng, Y.L., Peng, S.K.: Price competition and quality differentiation with multiproduct firms. J. Econ. 112(3), 207–223 (2014)CrossRef

Mintzberg, H.: Patent nonsense: evidence tells of an industry out of social control. CMAJ 175(4), 374–381 (2006)CrossRef

Spilker, B.: Guide to drug development—a comprehensive review and assessment. Lippincott Williams & Wilkins, Philadelphia (2009)

van de Vooren, K., Curto, A., Garattini, L.: Biosimilar versus generic drugs: same but different? Appl. Health Econ. Health Policy 13(2), 125–127 (2015)CrossRef

Feldschreiber, P., Breckenridge, A.: After thalidomide—do we have the right balance between public health and intellectual property. Rev. Recent Clin. Trials 10(1), 15–18 (2015)CrossRef

Friedman, L.M., Furberg, C.D., DeMets, D.L.: Fundamentals of clinical trials, 4th edn. Springer, New York (2010)CrossRef

10.

EMA. Annual Report 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Annual_report/2016/05/WC500206482.pdf. Accessed 21 Sept 2016

11.

Eichler, H.G., Baird, L.G., Barker, R., Bloechl-Daum, B., Børlum-Kristensen, F., Brown, J., et al.: From adaptive licensing to adaptive pathways: delivering a flexible lifespan approach to bring new drugs to patients. Clin. Pharmacol. Ther. 97, 234–246 (2015)CrossRef

12.

Ecorys—Research and Consulting. Competitiveness of the EU market and industry for pharmaceuticals. European Commission 2009. Ecorys, Rotterdam (2009)

13.

Garattini, L., Curto, A., Freemantle, N.: Pharmaceutical price schemes in Europe: time for a ‘Continental’ one? Pharmacoeconomics 34(5), 423–426 (2016)CrossRef

14.

Giuliani, G., Selke, G., Garattini, L.: The German experience in reference pricing. Health Policy 44(1), 73–85 (1998)CrossRef

15.

Porter, M.E.: What is value in health care? N. Engl. J. Med. 363(26), 2477–2481 (2010)CrossRef

16.

Garattini, L., Casadei, G.: Health technology assessment: for whom the bell tolls? Eur. J. Health Econ. 9(4), 311–312 (2008)CrossRef

17.

Godman, B., Shrank, W., Wettermark, B., et al.: Use of generics—a critical cost containment measure for all healthcare professionals in Europe? Pharmaceuticals 3(8), 2470–2494 (2010)CrossRef

18.

Gates, C.: Patenting the life sciences at the European patent office. Cold Spring Harb. Perspect. Med. 4(12), a020792 (2014)CrossRef

19.

Garattini, L., Curto, A.: European Medicines Agency: leave the UK but remain the same? J. R. Soc. Med. 109(9), 324–325 (2016)CrossRef

20.

Garattini, L., Curto, A., Padula, A., Freemantle, N.: Real-world evidence in economic evaluations: really realistic? J. R. Soc. Med. 109(11), 404–407 (2016)CrossRef

21.

Schneeweiss, S.: Reference drug programs: effectiveness and policy implications. Health Policy 81(1), 17–28 (2007)CrossRef

22.

Garattini, L., Padula, A.: Between pharmaceutical patents and European patients: is a compromise still possible? Expert Opin. Ther. Pat. (2017). doi:10.1080/13543776.2017.1350648 CrossRefPubMed

23.

Garattini, L., Koleva, D., Casadei, G.: Modeling in pharmacoeconomic studies: funding sources and outcomes. Int. J. Technol. Assess. Health Care 26(3), 330–333 (2010)CrossRef

Title: Competition in pharmaceuticals: more product- than price-oriented?
Authors: Livio Garattini
Anna Padula
Publication date: 01-01-2018
Publisher: Springer Berlin Heidelberg
Published in: The European Journal of Health Economics / Issue 1/2018
Print ISSN: 1618-7598
Electronic ISSN: 1618-7601
DOI: https://doi.org/10.1007/s10198-017-0932-4

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Competition in pharmaceuticals: more product- than price-oriented?

Excerpt

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2018

Cost-effectiveness analysis of the use of daclatasvir + sofosbuvir + ribavirin (16 weeks and 12 weeks) vs sofosbuvir + ribavirin (16 weeks and 24 weeks) for the treatment of cirrhotic patients affected with hepatitis C virus genotype 3 in Italy

Investigating social inequalities in older adults’ dentition and the role of dental service use in 14 European countries

A methodological framework for assessing agreement between cost-effectiveness outcomes estimated using alternative sources of data on treatment costs and effects for trial-based economic evaluations

Healthcare utilization and costs in primary care patients with dementia: baseline results of the DelpHi-trial

Patient preferences: a Trojan horse for evidence-based medicine?

Good jobs, good pay, better health? The effects of job quality on health among older European workers